XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Símbolo de cotizaciónXOMA
Nombre de la empresaXoma Royalty Corp
Fecha de salida a bolsaJun 06, 1986
Director ejecutivoMr. Owen P. Hughes, Jr.
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 06
Dirección2200 Powell Street
CiudadEMERYVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94608
Teléfono15102047200
Sitio Webhttps://xoma.com/
Símbolo de cotizaciónXOMA
Fecha de salida a bolsaJun 06, 1986
Director ejecutivoMr. Owen P. Hughes, Jr.
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos